Evidence map›Paper›PMID 19091776›Full record

ArticleInternational journal of epidemiology2009

Point-counterpoint. The triumph of the null hypothesis: epidemiology in an age of change.

Wasim Maziak

Abstract read
In one paragraph

Article in International journal of epidemiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Is uncertainty in complex disease epidemiology resolvable?Emerging themes in epidemiology · 2015
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Wasim MaziakUniversity of Memphis, School of Public Health, Memphis, TN 38152, USA. wmaziak@memphis.edu

Funding

Responding to the changing tobacco epidemic in the Eastern Mediterranean RegionR01DA024876 · NIDA · UNIVERSITY OF MEMPHIS · PI MAZIAK, WASIM · 2007 to 2011
$1.6M
NIDA NIH HHS R01DA024876-01
6 · The paper itself

Abstract

The recent confusion concerning the relation between hormone replacement therapy and cardiovascular disease has stirred a new wave of debate about the value and future of epidemiology. Opponents of epidemiology suggest an ever-diminishing role in an age of small risks and complex diseases, yet proponents are not in consensus about how to adapt their discipline to the challenges associated with ageing societies and changing disease patterns. While epidemiology is likely to be increasingly called upon to make sense of the risks involved with these changes, wading into this era with a mindset and tools that were derived from epidemiology's 'golden era' of tackling major risk factors, has created more confusion than understanding. Increasingly, we need to downsize epidemiology to what is testable, measurable, and relevant, based on robust methodology and public health rationale. Applying an evolutionary perspective, that views health problems of modernity as a manifestation of the mismatch between our ancient genes and hi-tech lifestyles, can provide guidance for a 21st century research agenda.

Indexed as

AsthmaBiological EvolutionChronic DiseaseEnvironmentEpidemiologic MethodsEpidemiologyHumansLife Style

Identifiers

PMID19091776
PMCPMC2734074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.